Compare CLPT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPT | LYEL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 490.1M |
| IPO Year | 2009 | 2021 |
| Metric | CLPT | LYEL |
|---|---|---|
| Price | $10.92 | $21.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $21.50 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 930.3K | 96.5K |
| Earning Date | 04-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,390,000.00 | $61,000.00 |
| Revenue This Year | $18.93 | N/A |
| Revenue Next Year | $51.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.04 | N/A |
| 52 Week Low | $8.63 | $0.39 |
| 52 Week High | $30.10 | $45.00 |
| Indicator | CLPT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 41.37 |
| Support Level | $10.57 | $21.27 |
| Resistance Level | $11.69 | $27.30 |
| Average True Range (ATR) | 1.00 | 1.85 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 34.09 | 9.38 |
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.